Ahpra registration PHY0002298174
How these guides are written and reviewed →
Postural orthostatic tachycardia syndrome (POTS) is a disorder of the automatic nervous system in which the heart races on standing up, causing dizziness, palpitations, fatigue and brain fog. It reflects a problem with how the body controls heart rate and blood flow with position, not a primary heart disease. Management is mostly non-drug: increasing fluids and salt, compression garments, and a careful, graded exercise programme that often starts lying down or seated. Symptoms can improve a great deal with consistent effort. This page explains POTS and how it is managed.
POTS is a chronic disorder of autonomic regulation characterised by an exaggerated heart rate response to upright posture in the absence of orthostatic hypotension. It is most common in adolescent and young adult women, frequently follows viral illness (including SARS-CoV-2), and is closely associated with hypermobile Ehlers-Danlos syndrome and mast cell activation syndrome.
Definition
POTS is defined as a sustained increase in heart rate of ≥30 bpm (≥40 bpm in adolescents aged 12–19) within 10 minutes of standing or head-up tilt, with associated symptoms of orthostatic intolerance, in the absence of orthostatic hypotension and other identifiable cause. Symptoms must be present for at least 3 months.1
Pathophysiology
POTS is heterogeneous and includes hyperadrenergic, neuropathic, hypovolaemic, and post-viral subtypes (frequently overlapping). Mechanisms include autonomic neuropathy with venous pooling, hypovolaemia, increased sympathetic activity, reduced cerebral autoregulation, and autoimmunity to autonomic receptors. Deconditioning is often a consequence rather than primary cause but contributes to perpetuation.
Co-morbidities
Hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders, mast cell activation syndrome, chronic migraine, fibromyalgia, irritable bowel syndrome, endometriosis, autoimmune disease, long COVID, ME/CFS, and anxiety. The triad of POTS, hEDS, and MCAS is increasingly recognised.
Prevalence
POTS prevalence is estimated at 0.2–1% in the general population, with prevalence rising substantially in the wake of the COVID-19 pandemic. Female-to-male ratio is approximately 4–5:1, with onset most commonly in the second and third decades.
Causes and triggers
Post-viral (Epstein-Barr, SARS-CoV-2, influenza, gastrointestinal viruses), post-surgical, post-traumatic, pregnancy and postpartum, growth spurt in adolescents, and gradual onset without identifiable trigger.
Symptoms
Lightheadedness and pre-syncope on standing, palpitations, exercise intolerance, fatigue, brain fog, headache, blurred vision, tremor, nausea, abdominal pain, sweating disturbance, sleep disturbance, and exaggerated symptoms in heat. Many patients describe deconditioning despite previously high baseline fitness.
Diagnosis
Active stand test
The 10-minute active stand test (also called the NASA Lean Test) is the most accessible diagnostic test in primary care. Heart rate and blood pressure are recorded supine after 5–10 minutes of rest, then at 1, 3, 5, 7, and 10 minutes of standing. A sustained HR increase ≥30 bpm (≥40 in adolescents) with symptoms supports the diagnosis.2
Tilt-table testing
Head-up tilt-table testing is the reference standard and is used when the active stand test is equivocal, syncope is present, or to distinguish POTS from other forms of orthostatic intolerance (orthostatic hypotension, neurally mediated syncope).
Exclusion of mimics
Exclusion of dehydration, anaemia, hyperthyroidism, phaeochromocytoma, primary cardiac arrhythmia, deconditioning, and medication-induced tachycardia. Baseline investigations: FBC, U&E, TFT, plasma metanephrines if hyperadrenergic features prominent, morning cortisol if indicated, ECG, and Holter monitor.
Assessment for associated conditions
Screening for hypermobile EDS using the Beighton score and clinical criteria, screening for mast cell activation features, sleep assessment, mental health screening, and review for autoimmune disease.
Heart rate variability and autonomic function testing
Heart rate variability (HRV) is the beat-to-beat variation in cardiac cycle length and reflects the balance between sympathetic and parasympathetic input to the sinoatrial node. Reduced HRV is a marker of autonomic dysregulation and is consistently found in POTS, particularly the post-viral and long COVID subtypes. While not used as a sole diagnostic test, HRV adds complementary objective evidence of autonomic dysfunction and provides a measurable outcome over time.
HRV can be measured by short-term ECG recording (5-minute resting protocol), 24-hour Holter monitoring, or by validated consumer wearables (chest straps, photoplethysmographic wrist devices) used under standardised conditions. Key indices include time-domain measures (RMSSD, SDNN), frequency-domain measures (high-frequency power as a parasympathetic marker, low-frequency power and LF/HF ratio with caveats around interpretation), and non-linear measures (sample entropy, Poincaré plot indices).
Formal autonomic function testing — performed in specialist autonomic laboratories — includes Valsalva manoeuvre with continuous beat-to-beat blood pressure monitoring, deep breathing heart rate variability (E:I ratio), 30:15 ratio on standing, quantitative sudomotor axon reflex testing (QSART), and thermoregulatory sweat testing. These are used when the clinical picture is complex, autonomic neuropathy is suspected, or to inform subtyping in research and tertiary centres.
For physiotherapy practice, the clinical value of HRV is twofold. First, it provides an objective baseline and progress marker for autonomic dysfunction that complements symptom diaries and active stand tests. Second, HRV-guided training — adjusting exercise intensity and recovery based on morning HRV trends — is an emerging approach in POTS and long COVID rehabilitation that may reduce the risk of post-exertional symptom exacerbation. Wearable HRV monitoring is now accessible enough to be incorporated into community physiotherapy programmes for selected, motivated patients.
Management
Non-pharmacological — first-line
Increase fluid intake to 2.5–3 L per day, increase salt intake to 8–10 g per day (in the absence of contraindication), wear waist-high or abdominal compression garments, avoid prolonged standing in heat, sleep with the head of the bed elevated, and address sleep, mood, and pacing.3
Structured exercise reconditioning
Structured exercise reconditioning is the most effective long-term treatment for POTS. Programmes commence in recumbent or semi-recumbent positions (rowing, recumbent bike, swimming) to bypass orthostatic load, progress over 3–6 months to upright exercise, and combine aerobic and lower-limb resistance work. The Dallas (Levine) and CHOP protocols are well-validated frameworks.4,5,6
Programmes need to be adapted to PESE in post-viral and long COVID POTS, where standard graded protocols can cause sustained worsening. Pacing and heart-rate-cap-based progression are essential in this subgroup.
Pharmacotherapy
Pharmacotherapy is added when non-pharmacological measures and reconditioning are insufficient. Options include beta-blockers (low-dose propranolol or metoprolol), ivabradine (often well-tolerated and effective for heart rate control without blood pressure effects), midodrine (for venous pooling and neuropathic phenotype), fludrocortisone (for hypovolaemic phenotype), pyridostigmine, and clonidine or methyldopa for hyperadrenergic phenotype.7
Treatment of associated conditions
Mast cell activation features may respond to H1 and H2 antihistamines, mast cell stabilisers, and identification of triggers. Hypermobile EDS requires proprioceptive and stability physiotherapy. Migraine, IBS, and mood disorders are treated conventionally.
Australian referral pathways
POTS is managed in Australia by a small number of cardiology, neurology, and immunology services with specific expertise; many patients are managed in primary care with allied health input. Australian POTS Foundation provides patient information and peer support.
Medications
First-line agents
Ivabradine (selective sinus node inhibitor; useful when blood pressure is borderline), low-dose beta-blockers (propranolol or metoprolol).
Volume expansion
Fludrocortisone, intravenous saline in selected refractory cases (not for long-term routine use).
Vasoconstrictors
Midodrine for neuropathic phenotype with venous pooling.
Other
Pyridostigmine (cholinesterase inhibitor; can improve postural tachycardia), clonidine or methyldopa for hyperadrenergic features, low-dose stimulants in selected cases under specialist supervision.
Multi-system manifestations
Hypermobile Ehlers-Danlos syndrome and joint hypermobility
Joint hypermobility and connective tissue laxity are present in a substantial minority of POTS patients. Proprioceptive and stability training, pacing, and avoidance of high-impact loading are central physiotherapy considerations.8
Mast cell activation syndrome
Flushing, urticaria, food and environmental sensitivities, abdominal symptoms, and reactions to medications and exercise. Trigger avoidance and antihistamine therapy under specialist guidance.
Gastrointestinal dysmotility
Nausea, early satiety, gastroparesis, IBS-like symptoms. Small frequent meals, low-fat low-fibre meals during flares, and prokinetics in selected cases.
Mental health
Anxiety and depression frequently co-exist and are bidirectionally related to symptom burden. POTS is not a psychiatric disorder, but psychological support is an important component of holistic care.
Living with POTS
Daily routine
Avoid prolonged standing, take care rising from supine or seated positions, drink fluids on waking, eat small frequent meals, avoid prolonged hot showers, exercise in cooler parts of the day, and use compression garments consistently.
Exercise progression
Long-term adherence to structured exercise reconditioning is the strongest predictor of recovery. Recumbent exercise should be continued indefinitely in many patients, with upright load added as tolerated. Progress is measured over months, not weeks.9
School, work, and driving
Workplace and educational adjustments (ability to sit, hydrate, take breaks, work flexibly) are often necessary. Symptomatic POTS with pre-syncope is a relative concern for driving safety; medical review and reporting obligations should follow Austroads guidance.
Pregnancy
POTS does not preclude pregnancy. Symptoms commonly improve in the second and third trimesters but may flare postpartum. Pre-pregnancy specialist review is recommended.
Prognosis
Most patients experience meaningful improvement with structured reconditioning, lifestyle measures, and (where required) pharmacotherapy. A substantial minority continue to have significant symptoms long-term, particularly in post-viral and overlap phenotypes. Early diagnosis and access to structured care are the strongest predictors of good outcome.10
Role of the physiotherapist
A graded, largely recumbent-to-upright exercise programme (recumbent bike, rowing, swimming progressing toward upright work) is a cornerstone of POTS management. The physiotherapist delivers this carefully progressed reconditioning, combines it with lower-limb strengthening and pacing, and educates on fluid, salt and posture strategies.
Warning signs
Part 1 · References
- Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015;12(6):e41–e63.
- Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome and related disorders of chronic orthostatic intolerance. Can J Cardiol 2020;36(3):357–372.
- Bourne KM, Sheldon RS, Hall J, et al. Compression garment reduces orthostatic tachycardia and symptoms in patients with postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2021;77(3):285–296.
- Fu Q, Vangundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2010;55(25):2858–2868.
- Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension 2011;58(2):167–175.
- George SA, Bivens TB, Howden EJ, et al. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm 2016;13(4):943–950.
- Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2021;77(7):861–871.
- Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet 2017;175(1):8–26.
- World Physiotherapy. Safe rehabilitation approaches for people living with long COVID: physical activity and exercise. London: World Physiotherapy; 2021.
- Fedorowski A, Sutton R. Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome. Nat Rev Cardiol 2023;20(5):281–282.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
Supervised exercise, breathing technique and self-management education are the mainstay of cardiorespiratory physiotherapy for this condition.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. Postural orthostatic tachycardia syndrome is defined by a sustained heart-rate rise of at least 30 bpm (40 bpm in adolescents) within ten minutes of standing, without orthostatic hypotension, plus chronic orthostatic symptoms — and the mechanisms are heterogeneous, including hypovolaemia, hyperadrenergic drive, neuropathic denervation and deconditioning.1 Exercise training is the intervention with the best evidence, which places physiotherapy at the centre of management, provided the programme is built to the recumbent-first pattern rather than a standard aerobic prescription.2,3
Exercise and non-pharmacological evidence
- Structured exercise training reverses the physiology. Progressive training beginning in recumbent or semi-recumbent positions increased blood volume, cardiac size and stroke volume and improved or resolved orthostatic tachycardia in a majority of patients.2,4
- Training outperformed beta blockade for symptom burden and quality of life in comparative study, and was better tolerated.4
- Community delivery works: the international POTS registry showed a three-month home-based version of the same protocol improved symptoms and function outside specialist centres, with attrition as the main limitation.3
- Compression garments reduce orthostatic tachycardia and symptoms, with abdominal and full lower-body compression more effective than calf compression alone.5
- Fluid and sodium loading (typically 2–3 litres of fluid and increased salt intake, where not contraindicated) is standard first-line management, with acute intravenous saline reserved for crises.1
- Ivabradine reduced heart rate and improved quality of life in a randomised placebo-controlled trial in hyperadrenergic POTS, without lowering blood pressure — useful where beta blockade is not tolerated.6
Overlap syndromes that change the prescription
- POTS following COVID-19 infection is now a common presentation, and frequently coexists with post-exertional symptom exacerbation — in which case symptom-titrated pacing, not progressive exercise, is the starting point.7,8
- Hypermobility spectrum disorders and hypermobile Ehlers–Danlos syndrome commonly coexist, adding joint pain, proprioceptive deficit and fatigue that shape modality choice and load progression.1,9
- Deconditioning is both consequence and contributor, and the sequence matters: volume expansion and compression first, then recumbent conditioning, then upright work.2,10
Physiotherapy implications
- Start recumbent or semi-recumbent — rowing, recumbent cycling, swimming — and progress toward upright exercise over months rather than weeks. Beginning with walking or standing work is the commonest reason a programme fails.2,3
- Build the lower body deliberately: quadriceps, glutes and calves act as the peripheral muscle pump, and strength work is part of the treatment, not an add-on.
- Layer the basics before load: fluid and salt, abdominal and lower-limb compression, avoiding prolonged standing and heat, small frequent meals, and adequate sleep with head-of-bed elevation where helpful.1,5
- Teach counter-manoeuvres — leg crossing, squatting, calf pumping, hand gripping — for symptomatic moments, and teach the patient to recognise pre-syncope early.
- Screen for post-exertional symptom exacerbation before prescribing progression; where present, pace to a sustainable baseline and progress by consistency rather than intensity.8
- Use heart rate as data, not as a stop rule: tachycardia on standing is the diagnosis, so treat symptoms and recovery as the guide and expect high heart rates during early upright work.
- Escalate true syncope with injury, exertional chest pain, orthostatic hypotension (a different diagnosis), unexplained weight loss, or symptoms that worsen steadily despite an appropriate programme — secondary causes need excluding.1
Clinical reasoning
- Confirm the diagnosis with an active stand or tilt measurement rather than accepting the label; orthostatic hypotension, inappropriate sinus tachycardia, anxiety and anaemia all mimic it.1
- Ask what happens 12–72 hours after activity. That answer decides between progressive training and pacing, and getting it wrong causes avoidable harm.8
- Progress is measured in tolerated upright time and function, not in heart rate alone.
- Expect a long arc: meaningful change typically takes three months or more, and telling patients this up front prevents early abandonment.3
Evidence gaps
- Exercise trials are small, largely unblinded and conducted in specialist centres, with high attrition in community settings.3,4
- No trial has compared progressive exercise with symptom-titrated pacing in patients who have both POTS and post-exertional symptom exacerbation — the key clinical question.8
- Optimal compression pressure, garment type and duration of wear are undefined.5
- Long-term outcomes, relapse rates and the natural history of post-viral POTS remain poorly characterised.7
References for the clinical evidence summary
- Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015;12(6):e41–e63.
- Fu Q, Vangundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2010;55(25):2858–2868.
- George SA, Bivens TB, Howden EJ, et al. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm 2016;13(4):943–950.
- Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension 2011;58(2):167–175.
- Bourne KM, Sheldon RS, Hall J, et al. Compression garment reduces orthostatic tachycardia and symptoms in patients with postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2021;77(3):285–296.
- Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2021;77(7):861–871.
- Fedorowski A, Sutton R. Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome. Nat Rev Cardiol 2023;20(5):281–282.
- World Physiotherapy. Safe rehabilitation approaches for people living with long COVID: physical activity and exercise. London: World Physiotherapy; 2021.
- Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet 2017;175(1):8–26.
- Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome and related disorders of chronic orthostatic intolerance. Can J Cardiol 2020;36(3):357–372.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.